INmune Bio Appoints Rare Disease and Biopharma Veterans Duane Clark and James Sapirstein to Board

INmune Bio has appointed R. Duane Clark II and James Sapirstein to its Board of Directors, enhancing the company’s commercial and strategic leadership as it advances Ebstrocel.

INmune Bio develops therapies designed to reprogram patients’ innate immune systems. Ebstrocel, the lead product from the company’s CORDStrom platform, is an investigational pooled allogeneic, umbilical cord-derived mesenchymal stromal cell therapy being developed for recessive dystrophic epidermolysis bullosa (RDEB).

Duane Clark brings more than 40 years of global pharmaceutical and biotechnology leadership, with particular depth in rare diseases, immunology and specialty-product commercialization. He currently serves as General Manager, U.S. Rare Diseases at Sanofi, leading a business spanning seven rare-disease brands with full profit-and-loss responsibility.

Earlier in his career, he led Sanofi’s U.K. and Ireland multiple sclerosis business and held commercial and business-development roles at CTI Clinical Trial & Consulting Services, Encysive Pharmaceuticals, Astellas Pharma, Ortho Biotech and Marion Laboratories.

James Sapirstein brings more than 40 years of biopharmaceutical leadership spanning business development, licensing, commercialization, capital formation and public-company leadership experience. His career includes senior roles at Gilead Sciences, Bristol Myers Squibb, Hoffmann-La Roche, Eli Lilly and Serono Laboratories.

He also founded and led Tobira Therapeutics, which Allergan later acquired in a transaction with total potential consideration of up to approximately $1.7 billion, including contingent milestone payments.

“These appointments bring capabilities directly aligned with INmune Bio’s next stage of growth,” said David Moss, Chief Executive Officer of INmune Bio.

Source link